Drugs for the treatment of endometrial hyperplasia

Drugs for the treatment of endometrial hyperplasia are medicines that help eliminate the pathological disease. Hyperplasia must be treated comprehensively, and the therapy must consist of several successive stages. At each stage, certain medicines are used that correspond to a particular form of endometrial hyperplasia.

Complex treatment with the use of drugs means four stages. At the first stage, it is necessary to stop the bleeding, at the second stage, conduct hormone therapy, normalize the menstrual cycle, undergo regular examinations and preventive drug intake.

Drugs for the treatment of endometrial hyperplasia are divided into:

• Single-phase and three-phase oral contraceptives (duration of use is not less than six months).
• Pure gestagens – Norclote, Duphaston, Medroxyprogesterone (duration of use at least six months).
• Antiestrogens – Danazol, Gestrinone (continuous administration for six months).

Let's look at how the entire process of treating endometrial hyperplasia goes from the first to the last stage, and what medications are taken during the treatment.

1. At the first stage, it is necessary to stop the bleeding. For this purpose, the woman is prescribed oral contraceptives that contain gestagens and estrogens (Zhanin, Yarina, Marvelon, Logest). The drugs are taken in a hemostatic mode. If the woman's condition does not improve, then doctors perform curettage of the uterine cavity. And to stop the bleeding, a number of hemostatic drugs are administered (1% solution of Vikasol, Dicynone, 10% solution of calcium gluconate). If necessary, the patient is administered blood substitutes and drugs that normalize the water-salt balance in the body (Stabizol, Refortan). In some cases, the woman is given intravenous injections of vitamins B, C, rutin and folic acid.
2. The second stage of treatment is hormone therapy. The treatment is aimed at reducing the tendency of the endometrium to grow. The doctor creates an individual treatment plan for the patient and selects hormonal drugs.

• As a rule, gestagens are used (Norkolut, Progesterone, Duphaston, Depo-Provera).
• The doctor may prescribe drugs from the group of gonadotropin-releasing hormone (GnRH) agonists to eliminate disorders at the endocrine-metabolic level, normalize the functioning of the autonomic and central nervous system (Buserelin, Goserelin). Such drugs are taken from three to six months.
• In addition to the above-described drugs, combined oral contraceptives can be prescribed for the treatment of endometrial hyperplasia. Such multiphase drugs are taken during the menstrual cycle. There are single-phase contraceptives (Femoden, Marvelon, Janine, Miniziston) and three-phase (Triziston, Tristep).

4. The third stage of treatment is designed to restore ovulation, the menstrual cycle and the hormonal status of the woman. Thus, for women of reproductive age, the following drugs are used to stimulate ovulation: Clomiphene, Profasi, Phenobarbital, Metrodin. The dosage and duration of use are selected by the attending physician. If a woman is in menopause, the task of doctors is to stop cyclic menstruation and return stable menopause. For these purposes, drugs containing male sex hormones are used - Methyltestosterone, Testosterone.
5. At the last stage of treatment, the woman should undergo regular examinations, control ultrasound examinations and curettage, take a vitamin complex. If there is a suspicion of relapse of endometrial hyperplasia, the doctor prescribes oral contraceptives.

[ 1 ], [ 2 ], [ 3 ], [ 4 ]

Hormonal treatment of endometrial hyperplasia

Hormonal treatment of endometrial hyperplasia is designed to suppress pathological processes, i.e. stop the growth of the endometrium and inhibit the release of gonadotropic hormones and steroidogen in the ovaries. A number of drugs are used to treat endometrial hyperplasia, the use of which depends on the severity of proliferation.

• Combined compounds - COC estrogen-progestogen drugs. Most often, drugs containing third-generation progestogens are used, as they have a minimum of side effects and do not cause metabolic effects (Regulon, Mercilon, Silest, Marvelon).
• Progestogen drugs - used to treat endometrial hyperplasia by blocking the growth of the epithelium.
• GnRH agonists are used to treat various hormone-dependent pathologies. The most popular and effective drugs in this group are: Buseril, Goserelin, Triptorelin. The drugs are highly effective, and the positive therapeutic effect is achieved by blocking the affected cells.

Hormonal treatment of endometrial hyperplasia is a kind of alternative to surgical intervention. Thus, in case of uterine bleeding, hormone-containing IUDs are used. And to prevent relapses of the disease and restore hormonal balance, combined oral contraceptives are used.

Hormonal treatment of endometrial hyperplasia in patients of reproductive age

The type of treatment and the drugs used depend on absolute or relative hyperestrogenism. Thus, COCs are prescribed for women with relative hyperestrogenism, and gestagens for those with absolute hyperestrogenism. If a young patient is diagnosed with simple endometrial hyperplasia, a course of Medroxyprogesterone is prescribed for its treatment. If there is no therapeutic effect, the dosage is increased and continuous intake is prescribed (such treatment is also used for atypical endometrial hyperplasia).

Women of reproductive age who are contraindicated for systemic hormonal therapy and who need contraception are prescribed a hormone-containing IUD to treat endometrial hyperplasia. In addition to treating the underlying disease, the doctors' task is to restore the ovulatory menstrual cycle. For this purpose, ovulation stimulants are used.

If endometrial hyperplasia recurs, this indicates insufficient therapy or the presence of hormonally active structures in the ovaries. To clarify, the woman undergoes an endoscopic biopsy of the ovaries or resection during laparoscopy. If there are no morphological changes, this is a reason to continue hormonal therapy, but with higher doses of drugs. In some cases, the ineffectiveness of hormonal treatment for endometrial hyperplasia in women of reproductive age indicates the presence of infections and inflammatory processes.

Hormonal treatment of endometrial hyperplasia in pre- and perimenopausal patients

During the perimenopause, hormonal therapy consists of drugs that suppress estrogen production and mitotic activity of endometrial cells. Antigonadotropins, progestogens, and GnRH agonists are used for treatment. Very often, the choice of hormonal drug during the perimenopause is difficult, since hormonal treatment can be a relative or absolute contraindication.

Hormonal treatment without polyps and atypia during pre- and perimenopause is carried out with such drugs as: Norethisterone, Medroxyprogesterone, Goserelin. The duration of use is at least six months. In case of relapses of endometrial hyperplasia and internal endometriosis, indications for surgical intervention, i.e. removal of the uterus, are expanded.

Hormonal treatment of endometrial hyperplasia in postmenopause

To treat the disease in women during the postmenopausal period, hormonal therapy with prolonged gestagens, anticoagulants, and hepatoprotectors is used in continuous mode. At this stage, endometrial ablation is possible. Hormonal treatment is carried out with regular ultrasound examinations and cytological control. If endometrial hyperplasia recurs in postmenopause, then this is a direct indication for surgical intervention, that is, extirpation of the uterus with appendages.

Hormonal treatment of atypical endometrial hyperplasia

The only correct and effective method of treating this disease with atypia is complete removal of the uterus. But the question of organ amputation is individual for each woman. With the advent of highly effective synthetic hormonal drugs, the question of surgical intervention is not so acute. That is, hormonal treatment can cure the initial forms of endometrial cancer and endometrial hyperplasia with atypia. Gestagens (Medroxyprogesterone, Hydroxyprogesterone caproate), GnRH agonists (Goserelin, Buserelin), antigonadotropins (Danazol, Gestrinone) are used for treatment.

The results of hormonal treatment depend entirely on the type and nature of atypia. Thus, treatment with progestins is effective for structural atypia, but is ineffective for cellular atypia. Hormonal treatment is ineffective for atypical endometrial hyperplasia and ovarian and myometrium pathologies. Small doses of progestins and estrogens are added during treatment, which improves the results of therapy.

Organ-preserving hormone therapy should be carried out under strict medical supervision. The criterion for recovery in this case is complete atrophy of the endometrium. If the disease recurs after stopping taking hormonal drugs, the woman undergoes amputation of the uterus and ovaries.

Treatment of endometrial hyperplasia with duphaston

Treatment of endometrial hyperplasia with Duphaston is an effective hormonal therapy. Duphaston is a drug that is used to increase progesterone in the female body. The drug does not have androgenic, corticoid, estrogenic, anabolic or thermogenic effects.

The main indications for the use of the drug are the treatment of endometrial hyperplasia, dysmenorrhea and endometriosis. The drug is also effective in the treatment of infertility, which occurs due to luteal insufficiency. Duphaston is effective in various menstrual cycle disorders and dysfunctional uterine bleeding. The drug is effective as a hormone replacement therapy.

The drug is produced in the form of tablets, the active substance is dydrogesterone. In its molecular structure, pharmacological and chemical properties, the active substance is similar to natural progesterone. Since dydrogesterone is not a derivative of testosterone, it does not have side effects that are typical for synthetic progestogens. The drug selectively affects the endometrial layer and prevents the development of endometrial hyperplasia and carcinogenesis with excess estrogen.

The drug is not a contraceptive, so it makes it possible to conceive a child and maintain pregnancy even during treatment. Duphaston is quickly absorbed and absorbed in the gastrointestinal tract. The drug is excreted in the urine, usually in the form of glucuronic acid conjugates. For the treatment of endometrial hyperplasia, Duphaston is taken continuously at 10 mg three times a day, from the 5th to the 25th day of the cycle. Side effects of the drug are headache, migraine, increased sensitivity of the mammary glands, weakness, breakthrough uterine bleeding. Rash and other skin allergic reactions are possible. Duphaston is contraindicated in case of individual intolerance to the components of the drug. The drug is available only on prescription.

Treatment of endometrial hyperplasia with norcolut

Treatment of endometrial hyperplasia with Norcolut is a therapy with a drug that is very often used in gynecology. The drug is available in tablet form. Norcolut contains hormones that affect the condition of the uterine mucosa, i.e. the endometrium. The drug reduces the tone of the uterus and increases the amount of tissue in the mammary glands that are responsible for lactation.

The active substance of the drug is norethisterone, a substance that belongs to gestagens, but has the properties of estrogens and androgens. Therapeutic doses of the drug contribute to the suppression of pituitary ganadotropic hormones, which delays the maturation of follicles and prevents ovulation. After oral administration, the drug is quickly absorbed, the maximum concentration is observed 2 hours after administration. The drug is excreted by the liver, and the half-life is from 3 to 10 hours.

• The main indications for the use of the drug: menstrual irregularities, endometriosis, mastodynia, endometrial hyperplasia, adenomyoma of the uterus, cystic-glandular changes in the endometrium, uterine bleeding during menopause.
• The scheme for taking the drug is made by the doctor. The dosage and duration of treatment depend on the disease and pathologies that require treatment. So, if the drug is taken for cystic-glandular hyperplasia of the endometrium, then patients are prescribed 5-10 mg of the drug for 6-10 days. For uterine bleeding, the drug is taken in the same dosage, but from the 16th to the 15th day of the cycle. For hormonal disorders, the drug is taken for a long period of time at a dose of 5 mg.
• The use of the drug may cause side effects, which manifest as: headache, dyspepsia, weight gain or loss, breast engorgement, asthenia.
• Norcolut is contraindicated for use in atypical endometrial hyperplasia, malignant tumors of the mammary glands and reproductive organs. The drug is not prescribed to patients with epilepsy, liver, heart or kidney pathologies, blood clotting disorders, bronchial asthma.
• Norcolut is not recommended to be used simultaneously with hypoglycemic drugs, steroids and drugs that affect the functioning of the liver and kidneys. The drug is available only on prescription.

Treatment of endometrial hyperplasia with buserelin

Treatment of endometrial hyperplasia with buserelin is a hormonal therapy used in combination with other drugs. Buserelin suppresses the synthesis of testosterone and the hormone that causes the formation of the corpus luteum in the ovary. The use of the drug causes a kind of pharmacological castration, that is, a condition similar to the removal of the sex glands. Buserelin is well absorbed by the mucous membrane and creates high concentrations in the blood plasma.

• The main indications for the use of the drug are prostate cancer therapy, reduction of testosterone levels in the blood. The drug is used in complex hormonal treatment of endometrial hyperplasia.
• The drug is taken according to an individually prescribed regimen by the doctor. The duration and dosage depend on the form of hyperplasia, the patient's age and the individual characteristics of her body. Since the drug is available in the form of injections and nasal spray, the dosage should be strictly controlled by the attending physician.
• The drug causes side effects that manifest as hot flashes, digestive disorders, decreased libido and thrombosis. Buserelin is not prescribed for individual intolerance to the components of the drug.

Treatment of endometrial hyperplasia with Janine

Treatment of endometrial hyperplasia with Janine has proven its effectiveness. And this is not surprising, since the prognosis of any disease depends on how correctly the drugs for treatment are selected. During the treatment of endometrial hyperplasia, it is very important to normalize and restore the menstrual cycle. Conventional contraceptives do not always cope with this task due to the hormonal level. That is why Janine is used to treat endometrial hyperplasia.

Zhanin is a low-dose oral multiphase combined contraceptive drug that contains estrogen and gestagen. The drug's action is aimed at suppressing ovulation at the level of hypothalamic-pituitary regulation, changing the endometrium, which makes it impossible for a fertilized egg to implant, and changing the properties of cervical secretions, making them impermeable to sperm. The use of the drug makes the menstrual cycle regular, reduces the intensity of bleeding and the pain of menstruation.

• The main indications for the use of the drug are contraception. In case of endometrial hyperplasia, the drug is used in combination with hormonal therapy. Zhanin is effective in the treatment of this pathology in women of reproductive age, performing therapeutic, contraceptive and preventive functions.
• Failure to comply with the rules for using the drug, dosage and duration of use recommended by the doctor cause side effects. The main side effects of the drug Janine are manifested as enlargement, soreness and tension of the mammary glands, the appearance of discharge from the breast, breakthrough uterine bleeding and bloody discharge, gastrointestinal disorders, changes in libido, allergic reactions, changes in body weight, fluid retention and others.
• The drug is contraindicated for arterial and venous thrombosis, after heart attacks and strokes. The drug is prohibited for patients with a history of migraine and focal neurological symptoms, diabetes, pancreatitis, liver failure and kidney tumors. Janine is not used to treat atypical endometrial hyperplasia and malignant diseases of the genitals and mammary glands. The drug is not prescribed to pregnant women and during breastfeeding. Individual intolerance to one of the components of the drug is a contraindication to its use.
• In case of overdose, Janine causes vomiting, nausea, metrorrhagia, bloody discharge. In case of the above-described symptoms, symptomatic treatment is necessary, since there is no specific antidote.

Treatment of endometrial hyperplasia after curettage

Treatment of endometrial hyperplasia after curettage is a course of hormonal therapy. The choice of optimal drugs depends on the patient's age, concomitant diseases and the type of endometrial hyperplasia. Drugs for the treatment of endometrial hyperplasia are selected by the attending physician, individually for each woman.

• Most often, when treating endometrial hyperplasia after curettage, drugs containing gestagens are used, as they are suitable for women of all ages. Tablets are taken on the 16th to 25th day of the menstrual cycle, and the duration of therapy is 3-6 months. For treatment after curettage, the following gestagens are used: Norcolut, Norluten, Utrozhestan, Provera, 17-OPK, Progesterone, Depo-Provera.
• In case of complex endometrial hyperplasia, which is accompanied by endocrine-metabolic disorders in patients over 35 years old, drugs of the GnRH agonist group are used. The drugs are taken 50-150 mg daily, the course of treatment is combined with the intake of gestagens and takes from 3 to 6 months. The most effective drugs from this group are: Buserelin, Goserelin, Diphereline.
• In addition to GnRH agonists and gestagens, combined therapy with estrogen-gestagen drugs is used to treat endometrial hyperplasia after curettage. Medicines in this group can be monophasic and three-phase oral contraceptives. Such drugs are effective for treating endometrial hyperplasia in women under 35 years of age. Monophasic drugs are taken from day 5 to day 25 of the menstrual cycle, one tablet at a time, three-phase drugs - from day 1 to day 28 of the cycle. Effective monophasic combination drugs: Marvelon, Logest, Rigevidon, Miniziston, Janine, Femoden. Of the three-phase drugs, for the treatment of endometrial hyperplasia after the curettage procedure, the following are recommended: Triziston, Trikvalar, Tristep.

Please note that after a course of hormonal treatment, it is mandatory to undergo a control ultrasound examination and aspiration of the contents of the uterine cavity. As a rule, examinations are carried out three and six months after the start of hormonal treatment.

Mirena for endometrial hyperplasia

Mirena is used for hormonal therapy in endometrial hyperplasia. The clinical and pharmacological group of the drug is an intrauterine contraceptive. Mirena IUD, i.e. an intrauterine therapeutic system, consists of a white hormonal-elastomeric core, has a high release rate of the active substance of 20 mcg / 24 h, a T-shaped body with loops at one end and threads for removing the system. Mirena is placed in a conductor tube, while the system itself and the conductor do not have impurities. The active substance of the IUD is levonorgestrel.

Mirena IUD has a gestagenic effect, levonorgestrel is released into the uterine cavity. High concentrations of the active substance reduce the sensitivity of estrogen and progesterone receptors. Due to this, the endometrium becomes insensitive to estradiol and has a strong antiproliferative effect.

Mirena is effective in preventing endometrial hyperplasia and as a therapeutic and prophylactic agent for endometrial pathologies. The drug is administered into the uterus, the rate of release of the active substance is 20 mg per day, and after five years of using the drug, the rate decreases to 10 mg per day.

• The main indications for the use of the drug are contraception, prevention and treatment of endometrial hyperplasia during a course of estrogen replacement therapy.
• The drug is contraindicated during pregnancy and if there is a suspicion of it. Mirena is contraindicated in inflammatory diseases of the pelvic organs, malignant neoplasms of the cervix and uterus, cervical dysplasia, pathological bleeding of unknown etiology, cervicitis. The IUD is not used in case of congenital or acquired uterine anomalies, liver diseases and hypersensitivity to the components of the drug.
• The Mirena IUD is effective for five years and is used in women who are taking hormone replacement therapy in combination with transdermal or oral estrogen preparations.
• Before installing Mirena, it is very important to completely exclude pathological processes in the endometrium. Since in the first months after the installation of the coil, there may be irregular bleeding and bloody discharge. The system is removed after five years.
• Side effects of the Mirena IUD include nausea, headaches, bleeding, lengthening or shortening of the menstrual cycle. However, side effects usually only appear in the first month after the system is installed. The drug is available only with a doctor's prescription.

Orgametril for endometrial hyperplasia

Orgametril for endometrial hyperplasia is a monohormonal oral contraceptive used during hormonal therapy. The active substance of the drug is lynestrenol, a progestogen that is similar in its principle of action to natural progesterone. The substance affects the transformation processes in the endometrial layer in the uterine cavity and helps treat diseases associated with menstrual irregularities.

The drug is used as an adjuvant for the treatment of post- and premenopausal disorders caused by endometrial hyperplasia. Long-term use of the drug suppresses ovulation processes and menstrual functions. Orgametril is effective in the treatment of atypical hyperplasia.

• The main indications for the use of the drug are endometrial hyperplasia, malignant neoplasms and pathological processes in the endometrium, polymenorrhea, amenorrhea, premenstrual syndrome, mastopathy, endometriosis, menorrhagia and metrorrhagia, the need to suppress ovulation.
• The drug is taken orally with plenty of water. The treatment regimen using Orgametril is made by a doctor, individually for each patient. But, as a rule, when treating endometrial hyperplasia, the drug is taken at 2.5-5 mg per day, in the first two weeks of each month, in combination therapy with estrogen drugs.
• Side effects of Orgametril include nausea, diarrhea, headache. In some cases, the drug causes jaundice, chloasma, allergic reactions on the skin, decreased libido, weight gain or loss, breakthrough bleeding, anxiety, swelling and tension of the mammary glands.
• Orgametril is not prescribed in case of individual intolerance to the active substances of the drug, liver pathologies, jaundice, congenital disorders of cholesterol metabolism, porphyria, insulin-dependent diabetes mellitus, ectopic pregnancy and skin itching. With special caution, Orgametril is prescribed to patients with arterial hypertension, thromboembolism, depression and CHF.
• Since the active substance of the drug has low toxicity, there are no cases of overdose. Sometimes, patients develop symptoms of depression.
• The drug is available in tablet form, 30 pieces per package. The medicine is dispensed by prescription, the shelf life of Orgametril is five years from the date of manufacture indicated on the drug packaging.

Utrozhestan for endometrial hyperplasia

Utrozhestan for endometrial hyperplasia is an effective drug based on female sex hormones. The active substance of the drug is progesterone (a hormone of the corpus luteum of the ovary). The use of the drug promotes normal secretory transformations in the endometrium of the uterine cavity. Utrozhestan potentiates the transition of the mucous layer from the proliferative phase to the secretory phase. Thus, during fertilization of the egg, the drug causes changes in the endometrium, which promotes the development of the embryo, i.e. implantation. The antialdosterone effect of the drug promotes increased urination.

• The drug is prescribed for corrective therapy in case of endogenous progesterone deficiency. Oral use of Utrozhestan helps in the treatment of infertility caused by corpus luteum insufficiency, menstrual cycle disorders due to ovulation disorders, premenstrual syndrome and in combination with estrogen drugs for hormone replacement therapy in case of endometrial hyperplasia and climacteric syndrome.
• Intravaginal use of the drug helps maintain the luteal phase of the menstrual cycle in preparation for in vitro fertilization and egg donation. The drug is used to prevent endometriosis, endometrial hyperplasia, and uterine fibroids. Utrozhestan is effective in treating threats of abortion that arise due to progesterone deficiency.
• The drug is administered orally or intravaginally. The dosage and duration of use are specified by the attending physician. For example, in case of progesterone deficiency, women are prescribed 200-300 mg of the drug, which must be divided into evening and morning intake.
• Utrozhestan causes side effects that manifest as intermenstrual bleeding, dizziness a couple of hours after taking the drug, drowsiness, and hypersensitivity reactions.
• The drug is contraindicated for use in cases of bleeding from the genital tract of unknown origin, incomplete abortion, porphyria, a tendency to thrombosis, allergic reactions to the active substances of the drug. Utrozhestan is not prescribed to patients with malignant diseases of the reproductive organs and liver dysfunction.
• Overdose of Utrozhestan causes symptoms similar to the symptoms of side effects. As a rule, the symptoms of overdose disappear after reducing the dose of the drug.

Lindinet 30 for endometrial hyperplasia

Lindinet 30 is used for endometrial hyperplasia in hormonal therapy. The drug is a combined oral contraceptive. That is, the main indications for the use of the drug are contraception - prevention of unwanted pregnancy.

• Lindinet 30 is contraindicated for patients with hypersensitivity to the components of the drug, with migraine with focal neurological symptoms, with liver diseases and thromboembolic processes, arterial thrombosis. The drug is not prescribed to patients with hormone-dependent malignant diseases of the genital organs and mammary glands, that is, the drug is not effective in atypical endometrial hyperplasia.
• Side effects of Lindinet 30 are headaches, migraines, and low mood. The drug causes gastrointestinal disorders, changes in body weight, changes in vaginal secretion, soreness and engorgement of the mammary glands. In some patients, taking the drug causes fluid retention in the body and hypersensitivity reactions.

Visanne for endometrial hyperplasia

Visanne for endometrial hyperplasia is a gestagen. That is, the drug is used in hormonal therapy for the treatment of endometrial hyperplasia. The drug is available in tablet form. The active ingredient of the drug is micronized dienogest, a derivative of nortestosterone, which has antiandrogenic activity. The main indications for the use of the drug are the treatment of endometriosis, endometrial pathologies and endometrial hyperplasia of the uterus.

• The drug is taken orally, the drug is rapidly absorbed, and its bioavailability is about 91%. After oral administration, about 86% of the drug is excreted within 6 days, with the main part excreted in the first 25 hours, usually by the kidneys.
• The dosage of the drug is selected by the doctor, individually for each woman. As a rule, the duration of use of the drug is six months. Visanne can be taken on any day of the menstrual cycle, but the intake must be continuous, even if breakthrough bleeding from the vagina begins.
• In case of overdose, Visanne causes gastrointestinal disturbances, spotting, metrorrhagia. Symptomatic treatment is carried out in the above-described manifestations.
• Side effects of the drug may appear in the first months of taking it. The most common of them are: headache, decreased mood, bleeding and spotting from the vagina, acne.
• The drug is contraindicated in acute thrombophlebitis or venous thromboembolism, cardiovascular and arterial diseases, and diabetes. Visanne is not prescribed to women with severe liver diseases, including tumors, hormone-dependent malignant tumors, and vaginal bleeding of unknown origin. The drug is prohibited for the treatment of endometrial hyperplasia in children and adolescents under 18 years of age because the effectiveness and safety of such treatment have not been established.
• With special caution, Visanne is prescribed to patients with a history of ectopic pregnancy, chronic heart failure, depression and arterial hypertension.

[ 5 ]

Yarina for endometrial hyperplasia

Yarina for endometrial hyperplasia, is used in hormonal therapy as a low-dose monophasic oral contraceptive with an antiandrogenic effect. The main indications for the use of the drug are the prevention of unwanted pregnancy, that is, contraception. The drug is used in hormonal therapy for pathologies of the uterine endometrium. The drug is useful for women who suffer from acne and hormone-dependent fluid retention.

• The dosage and duration of use of the drug are selected by the doctor, individually for each woman. As a rule, with endometrial hyperplasia, Yarina is taken for six months.
• The drug causes side effects that manifest as soreness and discharge from the mammary glands, headache, gastrointestinal disturbances, changes in vaginal secretion, changes in body weight and hypersensitivity reactions.
• Yarina is not prescribed to patients with thrombosis, diabetes mellitus with vascular complications. In severe liver diseases, hormone-dependent malignant diseases of the genital organs, vaginal bleeding of unknown genesis and in case of hypersensitivity to any component of the drug.
• In case of overdose, the drug causes nausea, vomiting, vaginal bleeding. Treatment of overdose is symptomatic, as there is no specific antidote.

Regulon for endometrial hyperplasia

Regulon is used for endometrial hyperplasia as a combined contraceptive with an estrogen component and a gestagen. The mechanism of action of the drug is based on the suppression of gonadotropin production, which makes ovulation impossible, increases the density of cervical mucus, changes the processes in the endometrium and prevents sperm from penetrating into the uterine cavity.

• The main indications for the use of the drug are the treatment of dysfunctional uterine bleeding, hormonal therapy for endometrial hyperplasia, contraception, treatment of menstrual irregularities, PMS and dysmenorrhea.
• The dosage and duration of use of the drug are selected by the doctor, individually for each woman. Regulon is recommended to be taken from the first day of the menstrual cycle. The drug is taken one tablet per day, preferably at the same time.
• Side effects of Regulon manifest as gastrointestinal tract disorders, liver dysfunction, intermenstrual bleeding, vaginal flora disorders, decreased libido, vaginal secretion changes. In rare cases, Regulon causes increased blood pressure, weight gain, headaches, and allergic rashes.
• Regulon is contraindicated in case of individual intolerance to one of the components of the drug, during pregnancy and lactation. The drug is not prescribed to women with liver diseases, arterial hypertension, migraine, herpes type 2 and epilepsy. Regulon is contraindicated for patients with estrogen-dependent tumors, coagulation disorders, bleeding from the genital tract of unclear etiology and severe forms of diabetes mellitus.
• Overdose of the drug causes headache, cramps in the calf muscles, dyspepsia. Treatment of overdose is symptomatic, since there is no antidote.

Marvelon for endometrial hyperplasia

Marvelon is used for endometrial hyperplasia during hormonal treatment. The drug is an oral contraceptive. The main indications for the use of Marvelon are pregnancy prevention, i.e. contraception. The drug is taken from the first day of the menstrual cycle and for 21 days. Every day, a woman needs to drink one tablet of the drug, at the same time.

Marvelon is recommended to be taken only as prescribed by a doctor, since the drug is contraindicated in cases of liver dysfunction, inflammation of the gallbladder, a tendency to thrombosis and in the presence of malignant tumors. In some cases, the drug causes side effects in the form of weight gain and swelling of the mammary glands. Marvelon is available in the form of 10 mg tablets. One tablet contains the progestin desogestrel and the estrogen ethinyl estradiol.

Klayra for endometrial hyperplasia

Klayra for endometrial hyperplasia is a low-dose combined oral contraceptive. The drug is a multiphase drug, so it is well tolerated by patients of all ages. Klayra tablets have different colors, which indicates that they contain different doses of hormones. The drug is released with two inactive tablets, which allow you to take the contraceptive continuously. The contraceptive effect of the drug is due to the suppression of ovulation, a decrease in the sensitivity of the endometrium to the blastocyst and an increase in cervical mucus.

• The drug is used to reduce the duration and intensity of bleeding during menstruation. The drug reduces pain during premenstrual syndrome and menstruation. The hormonal low-dose contraceptive significantly reduces the risk of developing gynecological diseases and hypertrichosis.
• The main indications for the use of the drug are oral contraception in women of reproductive age. The drug is prescribed for combined treatment of endometrial hyperplasia or at the stage of hormonal therapy.
• The drug Klayra is taken orally, it is advisable to swallow the tablet whole and wash it down with a sufficient amount of water. Each package of the drug contains 26 colored tablets with active substances and two white placebo tablets. The drug is taken regardless of food intake, but at the same time. In the first days of taking Klayra, minor bloody discharge may appear.
• The drug causes side effects that provoke varicose veins, thrombosis, changes in blood pressure, and gastrointestinal disorders. Klayra provokes headaches, depressive states, migraines, and convulsions. Side effects can also affect the reproductive system, causing intermenstrual bleeding, vaginal dryness, enlarged and painful breasts, and the appearance of benign cysts in the breasts. In rare cases, Klayra causes allergic reactions in the form of acne, itchy skin and rashes, swelling, baldness, and herpes.
• The drug Klayra is contraindicated for use by patients with individual intolerance to the components of the drug. Tablets are prohibited for patients with lactase deficiency, glucose-galactose malabsorption syndrome. The drug is not prescribed to patients with thrombosis, angina attacks, vascular diseases, diabetes mellitus, numbness of the limbs and speech disorders.
• The drug is prescribed with special caution in cases of pancreatitis, liver diseases, atypical hyperplasia and hormone-dependent malignant tumors. Qlayra is not used in cases of vaginal bleeding of unknown etiology, during pregnancy or suspicion of pregnancy, in patients under 18 years of age and during lactation.
• Only after a doctor's permission, assessment of the risks and benefits of the drug, Qlaira is prescribed to patients with a history of breast cancer, stroke, hereditary angioedema, smoking patients and chloasma.
• An overdose of the drug is possible when taking high doses and exceeding the duration of use. In this case, women experience vomiting and vaginal bleeding. There is no specific antidote, so if symptoms of an overdose appear, it is necessary to wash out the stomach and take enterosorbent drugs.

Tranexam for endometrial hyperplasia

Tranexam is used for endometrial hyperplasia as a drug that affects tissue metabolism processes, i.e. endometrial growth. Tranexam is a fibrinolysin inhibitor. The drug has a local and systemic hemostatic effect. The drug has anti-inflammatory, anti-allergic, anti-tumor and anti-infective properties. After administration, Tranexam is evenly distributed in tissues, penetrating the blood-brain and placental barriers. The maximum concentration of the drug in the blood plasma is observed three hours after administration and lasts for 17 hours. It is excreted mainly by the kidneys.

• Indications for use of the drug are based on the action of its components. Tranexam is used as a hemostatic agent for bleeding and the risk of its development due to an increase in the amount of fibrinolysin in the blood. The drug is used for uterine and nasal bleeding, bleeding in the gastrointestinal tract, eczema, urticaria, skin rashes and allergic dermatitis. Tranexam is also effective as an anti-inflammatory agent.
• The drug is available in the form of tablets and a solution for intravenous drip administration. Thus, for the treatment of endometrial hyperplasia and prevention after cervical surgery, the drug is taken 15 mg three times a day for two weeks.
• Side effects of the drug appear on the part of the gastrointestinal tract, causing heartburn, vomiting and nausea, diarrhea, decreased appetite. Tranexam causes dizziness, drowsiness, weakness, visual impairment, tachycardia, skin rash, chest pain.
• The drug is contraindicated for patients with individual intolerance to the components of the drug, with subarachnoid hemorrhage. Tranexam is used with special caution in thrombosis, myocardial infarction, thrombophlebitis, renal failure and color vision disorders.

Rigevidon for endometrial hyperplasia

Rigevidon is used for endometrial hyperplasia during hormonal therapy. The drug is a combined oral contraceptive. Rigevidon is a multiphase drug, each tablet of the drug contains estrogenic and gestagenic components in equal quantities. The drug effectively protects against unwanted pregnancy, causes suppression of ovulation, increases the viscosity of cervical mucus and reduces the susceptibility of the endometrium to the blastocyst.

• The drug blocks luteinizing and follicle-stimulating hormones, slows down the maturation of the follicle and its rupture. The active components of the drug inhibit the ovulation process and prevent fertilization. Rigevidon has not only a contraceptive effect, but also helps to significantly reduce the risk of various gynecological diseases, including endometrial hyperplasia. The package of 21 tablets includes 7 placebo tablets. That is, taking Rigevidon does not cause hyperinhibition syndrome.
• The active substance of the drug is ethinyl estradiol. After oral administration, Rigevidon is rapidly absorbed in the gastrointestinal tract, the maximum concentration of the drug in the blood plasma is observed 1-2 hours after administration. The drug is excreted in the form of metabolites with feces and urine.
• The main indications for the use of Rigevidon are contraception in women of reproductive age. The drug can be used to correct functional disorders of the menstrual cycle, uterine bleeding, PMS, severe pain syndrome in the middle of the cycle.
• The drug can be taken only as directed by a doctor. Thus, before taking the drug, it is necessary to undergo a general clinical examination and a gynecological examination. The drug is taken orally, with a sufficient amount of water. Rigevidon is taken from the first day of the menstrual cycle, the duration of use is 21 days.
• The drug is well tolerated and causes virtually no side effects. But in some women, Rigevidon causes nausea, vomiting, headaches, increased fatigue, cramps in the calf muscles, and decreased libido. The drug can cause breast engorgement, allergic reactions on the skin, and intermenstrual bleeding. In rare cases, Rigevidon causes hyperpigmentation of the facial skin, weight changes, arterial hypertension, and changes in vaginal secretions. Side effects occur in the first three months of taking the drug.
• Rigevidon is contraindicated for use by patients with hypersensitivity to the components of the drug, with liver dysfunction, congenital elevated levels of bilirubin in the blood. The drug is not taken in hepatitis, chronic colitis, severe cardiovascular diseases, arterial hypertension. The drug is contraindicated in patients with endocrine disorders, including diabetes mellitus. The drug is not used to treat endometrial hyperplasia in patients with vaginal bleeding of unknown origin.
• Overdose of Rigevidon may cause headache, vomiting, nausea, vaginal bleeding, painful sensations in the epigastric region. There is no specific antidote, therefore, with the above symptoms, complete withdrawal of the drug is indicated. Patients undergo gastric lavage and are prescribed an enterosorbent. In rare cases, symptomatic therapy is required.

Depo-Provera for endometrial hyperplasia

Depo-Provera for endometrial hyperplasia is a gestagenic drug. The drug has gestagenic and corticosteroid activity. If the drug is taken by women of reproductive age, it helps prevent ovulation due to inhibition of follicle maturation. Depo-Provera is effective in the treatment of hormone-dependent malignant neoplasms, i.e. atypical endometrial hyperplasia. The drug's effectiveness is explained by its effect on hormone metabolism at the cellular level.

The drug is similar in its principle of action to progesterone, as it has a pyrogenic effect. High doses of Depo-Provera contribute to the treatment of oncological diseases. When administered intramuscularly, the active components of the drug are slowly released, which helps maintain low doses of the drug in the blood plasma.

The maximum concentration of the drug is observed 4-10 days after intramuscular administration. Binding to blood proteins is at the level of 95%. The active substances of the drug pass through the blood-brain barrier, so Depo-Provera is contraindicated for use during lactation. The half-life of the drug is 6 weeks, but the active substance - medroxyprogesterone acetate is detected in the blood even 9 months after use.

• The main indications for the use of the drug are based on the action of its components. Depo-Provera is used to treat oncological diseases, relapses and metastases of breast and endometrial cancer, kidney and prostate cancer. The drug is used to treat atypical endometrial hyperplasia, endometriosis and vasomotor manifestations during menopause. Depo-Provera is prohibited as a contraceptive in patients of childbearing age.
• The drug is administered intramuscularly, injecting the suspension into the gluteal or deltoid muscle. The duration of use and dosage are selected by the doctor, individually for each patient. If the drug is used to treat endometrial hyperplasia during the postmenopausal period, then Depo-Provera is prescribed in a short course. But when treating endometrial hyperplasia, the duration of use can be six months.
• Side effects of the drug depend on the nature of the disease and the frequency of use of the drug. Depo-Provera causes gastrointestinal disorders, liver dysfunction, headaches, impaired concentration, visual impairment and seizures. In some cases, the drug provokes thromboembolism of various localizations. Allergic reactions on the skin, menstrual irregularities, amenorrhea, mastodynia and others are also possible.
• Depo-Provera is contraindicated for use in case of individual intolerance to the components of the drug. The drug is prohibited for use during pregnancy and lactation, with vaginal bleeding of unknown etiology and with severe liver dysfunction. The drug is not used before the onset of the menstrual cycle.
• The drug is prescribed with special caution to patients with epilepsy, migraine, chronic renal and heart failure and bronchial asthma.
• High doses of the drug may cause overdose symptoms, which are typical for glucocorticosteroids. To eliminate side symptoms, it is necessary to adjust the dose of the drug, i.e. reduce it. No acute cases of overdose have been recorded.

[ 6 ], [ 7 ], [ 8 ]